Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to examine whether a larger dosage of estrogen than the one used today will secure the development of a normal sized uterus and increase the strength of the bones in girls and young women with Turner syndrome.

The purpose is also to evaluate whether aortic dilatation is present in this group of patients, and if the estrogen dosage will influence the emotional well-being and self-esteem of the patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Line Cleemann
• Collaborators: Novo Nordisk A/S; The County of Frederiksborg; The foundation of Kaptajnløjtnant Harald Jensen and Wife; The foundation of Mr. Ivan Nielsen; The foundation of Mrs. Olga Bryde
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Verified Turner syndrome

• Ages 10-25 years

Exclusion Criteria:

• Contraindications to the MR-scan

• Contraindications to the trial medication

• Severe or chronic sickness with impact on the parameters of the study or incompatibility with the trial medication

• Intake of medications with interactions with trial medication